▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Samsung BioLogics inks US$55m deal with India’s Sun Pharma

  • PUBLISHED :July 04, 2017 - 16:24
  • UPDATED :July 04, 2017 - 16:25
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Samsung BioLogics, the Samsung-affiliated contract drug manufacturing firm, said on July 4 it signed a long-term manufacturing agreement worth US$55 million with Sun Pharma to supply a new therapy for a skin disorder to the Indian drug maker.

Under the deal, the Korean company will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. 


Samsung BioLogics CEO Kim Tae-han (left) and Sun Pharma CEO Anil Kumar Jain



“Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards,” Samsung BioLogics CEO Kim Tae-han said in a press release.

Sun Pharma expects to launch the Tildrakizumab drug next year as it is under review by the U.S. Food and Drug Administration and the European Medicines Agency.

Since its foundation in 2011, this is Samsung BioLogics seventh contract agreement with a global pharmaceutical firm. Other agreements have been made with Merck, AstraZeneca, Roche and Bristol-Myers Squibb.

The existing order backlog of Samsung BioLogics stands at US$3.2 billion, according to the Korean firm‘s official.

“Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its good manufacturing practice-certified manufacturing facility to pharmaceutical companies,” Kim said.

Currently, Samsung BioLogics boasts a combined capacity of 182,000 liters at its two plants in Songdo, Incheon. Once its third plant is completed by end-2018, the capability will bolster to 362,000 liters, the world’s largest biopharma product manufacturing capability.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS